Skip to content

Study · Not a test of the peptide alone · 2000

4 results

Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.

Rekasi Z, Varga JL, Schally AV, Halmos G, Groot K, Czompoly T

Proceedings of the National Academy of Sciences of the United States of America1 Feb 2000Cited by 21 (Europe PMC)

PMID10655511 (opens in a new tab)PMCIDPMC15574 (opens in a new tab)DOI10.1073/pnas.97.3.1218 (opens in a new tab)PepBankPUB-10655511
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In rat pituitary and pineal cells, the GHRH antagonists JV-1-36, JV-1-38 and JV-1-42 did not change VIP-stimulated prolactin release or cAMP efflux but inhibited GHRH-stimulated GH release.

    In plain wordsIn rat cells in the lab, three GHRH-blocking analogs did not change the effect of VIP but blocked GHRH.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeEffect of GHRH antagonists on VIP-stimulated release
    Study

    ratn: not reported in source

    Superfused rat pituitary and pineal cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Previously reported GHRH antagonists JV-1-36, JV-1-38, and JV-1-42 proved to be selective for GHRH receptors, because they did not influence VIP-stimulated VPAC(2) receptor-dependent prolactin release from pituitary cells or VPAC(1) receptor-dependent cAMP efflux from pinealocytes but strongly inhib…
    1 context sentence
    Summary · context
    To characterize various peptide analogs for their antagonistic activity on receptors for GHRH and VIP, we developed assay systems based on superfusion of rat pituitary and pineal cells.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In rat pituitary and pineal cells, the GHRH-related analogs JV-1-50, JV-1-51 and JV-1-52 antagonized VIP receptors VPAC1 and VPAC2 to various degrees and kept GHRH antagonism.

    In plain wordsIn rat cells in the lab, three new analogs blocked VIP receptors to various degrees and still blocked GHRH.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVPAC1 and VPAC2 antagonism by JV-1-50, JV-1-51 and JV-1-52
    Study

    ratn: not reported in source

    Superfused rat pituitary and pineal cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Analogs JV-1-50, JV-1-51, and JV-1-52 showed various degrees of VPAC(1)-R and VPAC(2)-R antagonistic potency, although also preserving a substantial GHRH antagonistic effect.
    1 context sentence
    Summary · context
    To characterize various peptide analogs for their antagonistic activity on receptors for GHRH and VIP, we developed assay systems based on superfusion of rat pituitary and pineal cells.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In rat pituitary and pineal cells, the analog JV-1-53 was a highly potent VPAC1 and VPAC2 receptor antagonist with no inhibition of GHRH-evoked GH release.

    In plain wordsIn rat cells in the lab, the analog JV-1-53 strongly blocked VIP receptors and did not block GHRH.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVPAC1 and VPAC2 antagonism by JV-1-53
    Study

    ratn: not reported in source

    Superfused rat pituitary and pineal cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Analog JV-1-53 proved to be a highly potent VPAC(1) and VPAC(2) receptor antagonist, devoid of inhibitory effects on GHRH-evoked GH release.
    1 context sentence
    Summary · context
    To characterize various peptide analogs for their antagonistic activity on receptors for GHRH and VIP, we developed assay systems based on superfusion of rat pituitary and pineal cells.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In rat pituitary and pineal cells, the antagonistic activity of the analogs on GHRH and VIP receptors agreed with their binding affinity.

    In plain wordsIn rat cells in the lab, how strongly each analog blocked the receptors matched how tightly it bound them.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableAgreement of antagonism with receptor binding
    Study

    ratn: not reported in source

    Superfused rat pituitary and pineal cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The antagonistic activity of these peptide analogs on processes mediated by receptors for GHRH and VIP was consistent with the binding affinity.
    1 context sentence
    Summary · context
    To characterize various peptide analogs for their antagonistic activity on receptors for GHRH and VIP, we developed assay systems based on superfusion of rat pituitary and pineal cells.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.